Giovanni Luca Frassineti

Author

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ORCID

Also Known As

A Sobrero, Frassineti GL, Frassineti, Giovanni, Frassineti, Giovanni Luca, G Frassineti, G L Frassineti, G. Frassineti, G. L. Frassineti, G. Luca Frassineti, G.L Frassineti

296

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Istituti di Ricovero e Cura a Carattere Scientifico Ospedale G.B. Morgagni - L.Pierantoni Istituto Oncologico Veneto University of Bologna

About

Giovanni Luca Frassineti is an author at Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	34	2.3K
2	Health Sciences	9	9	547
3	Nursing	2	2	352
4	Engineering	1	1	214
5	Biomedical Engineering	1	1	214

Giovanni Luca Frassineti

109

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, The Lancet Oncology OncologyMedicineColorectal CancerPathologyUpfront Folfoxiri	2020	309
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum Vito Lorusso, C. F. Pollera, Mauro Antimi, European Journal of Cancer Surgical OncologyUrologyTransitional Cell CarcinomaUrinary TractMedicine	1998	289
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs Francesco� Fabbri, Silvia Carloni, Wainer Zoli, Cancer Letters EngineeringCancer DetectionMedicineColon Cancer CellsColorectal Cancer	2013	214
Systematic versus on-demand early palliative care: A randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life Marco Maltoni, Emanuela Scarpi, Monia Dall’Agata, European Journal of Cancer NursingFamily MedicinePalliative CareEnd-of-life CareSymptomatic Treatment	2016	182
Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial Marco Maltoni, Emanuela Scarpi, Monia Dall’Agata, European Journal of Cancer Palliative CareNursingFamily MedicineSystematic VersusEnd-of-life Care	2016	170
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial Alessandro Passardi, Oriana Nanni, Davide Tassinari, Annals of Oncology Gastrointestinal OncologyMedicineClinical TrialsColorectal CancerMetastatic Colorectal Cancer	2015	155
Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer Alessandro Passardi, Emanuela Scarpi, Luigi Cavanna, Oncotarget	2016	152
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly, Journal of Clinical Oncology	2022	120
Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. Thomas Yau, Vittorina Zagonel, Armando Santoro, Journal of Clinical Oncology PharmacotherapyDurable ResponsesPre-clinical PharmacologyOncologyClinical Trials	2020	110

Page 1